Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Medical - Instruments & Supplies

Healthcare
$3.60 +2.30%

+$0.37 today

Market cap
$158.01M
Beta
4.34
P/E (TTM)
99.1
EPS (TTM)
$0.16
52W Low $10.50High $55.65

Volume 0.09M

Average 0.03M

NNNN Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN

Gross Profit · Q4 FY2025 · quarter ended Dec 2025

Gross profit grows 80.6% year over year

Q4 FY2025 gross profit of $3.86M rose 80.6% year over year. Over 3 fiscal years it compounded at -12.2% a year.

Context

  • Gross profit amounted to 87.2% of revenue in FY2025, up 15.3 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$3.86M— QoQ
Last fiscal yearDec 2025
$8.51M+44.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+80.6%——
1 year+44.6%——
3-year CAGR-12.2%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
8.51M USD
Year-over-year change
+44.6%
4-year CAGR
+35.3%

Gross Profit vs competitors

How NNNN compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +44.6% is the 3rd highest of 9, against a peer median of +12.0%.
  • Gross profit amounts to 87.2% of revenue for NNNN, versus a peer median of 53.7%.
NNNN Competitors
Gross Profit for NNNN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYHCommunity Health Systems, Inc.LTM Mar 2026$11.53B USD+118.3%-39.6%53.7%
AVNSAvanos Medical, Inc.LTM Mar 2026$347.6M USD-7.9%-4.0%48.6%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$279.95M USD+53.8%+32.3%93.4%
SNDLSNDL Inc.LTM Mar 2026CA$254.82M CAD+3.3%+22.6%27.2%
ANGOAngioDynamics, Inc.LTM Feb 2026$167.69M USD+8.9%-1.6%53.5%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$106.66M USD——92.0%
TALKTalkspace, Inc.LTM Mar 2026$100.68M USD+15.1%+17.7%42.2%
GOSSGossamer Bio, Inc.LTM Mar 2026$55.3M USD-55.6%—99.6%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$25.11M USD+27.3%+18.8%61.8%
NNNNAnbio Biotechnology Class A Ordinary SharesFY2025$8.51M USD+44.6%-12.2%87.2%
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD———
Peer median (excluding NNNN) —+12.0%+17.7%53.7%

Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.43M23.54M6.71M8.19M9.76M
Cost of Revenue1.89M10.98M3.35M2.3M1.25M
Gross Profit2.54M12.56M3.36M5.89M8.51M
Gross Margin57.4%53.4%50.1%71.9%87.2%
Research & Development0200K134.7K454.23K227.19K
Selling, General & Admin86.1K2.17M1.27M3.44M1.78M
Operating Expenses86.1K2.37M1.4M3.89M2M
Depreciation & Amortization06.25K13.04K00
EBITDA2.54M10.03M2.27M2.57M6.51M
EBITDA Margin57.3%42.6%33.8%31.4%66.7%
Operating Income2.46M10.2M1.96M2M6.51M
Operating Margin55.5%43.3%29.2%24.4%66.7%
Interest Income042.25K165.34K337.51K160.28K
Interest Expense08K000
Other Income / Expenses79.94K(184.41K)292.78K377.48K717.46K
Income Before Tax2.54M10.01M2.25M2.37M7.23M
Pre-Tax Margin57.3%42.5%33.6%29.0%74.1%
Income Tax Expense00000
Net Income2.54M10.01M2.25M2.37M7.23M
Net Margin57.3%42.5%33.6%29.0%74.1%
EPS (Basic)0.030.070.020.060.16
EPS (Diluted)0.030.070.010.060.16
Weighted Avg Shares100M143.89M143.89M42.29M43.89M
Weighted Avg Shares (Diluted)100M143.89M187.78M42.29M43.89M

Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Intrinsic Alpha fair value

Locked

Current Price

$3.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.